HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
07. September 2021 10:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Reports Second Quarter 2021 Financial Results and Recent Highlights
12. August 2021 07:00 ET
|
HOOKIPA Pharma Inc.
Phase 1 HB-200 data recognized at premier oncology meetings, highlighting potential of novel arenaviral platform to deliver a new class of immunotherapeuticsHOOKIPA on track to report comprehensive...
Pre-clinical data on HOOKIPA’s arenaviral immunotherapeutic in melanoma published in Nature Communications
05. August 2021 05:30 ET
|
HOOKIPA Pharma Inc.
HOOKIPA’s arenaviral platform technology demonstrated ability to modulate the tumor microenvironment and induce potent melanoma-specific T cell responsesA single, intra-tumoral injection of the...
HOOKIPA Pharma to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
03. August 2021 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Aug. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in June
10. Juni 2021 07:30 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, June 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
07. Juni 2021 18:00 ET
|
Hookipa Pharma Inc
Novel arenaviral therapeutic HB-200 generates outstanding tumor antigen-specific CD8+ T cell responses (average of 6 percent and up to 40 percent of T cell pool)To-date, HB-201 monotherapy has shown...
HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO
20. Mai 2021 07:00 ET
|
Hookipa Pharma Inc
Data from first-in-human Phase 1 study of arenaviral therapeutics, including first data on HB-201/HB-202 alternating 2-vector therapy and expanded data on HB-201, to be featured as oral...
HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent Highlights
12. Mai 2021 07:00 ET
|
Hookipa Pharma Inc
Oncology programs advance with preliminary Phase 1 immunogenicity data showing robust antigen-specific CD8+ T cell response after one dose of HB-201 or HB-202; clinical results consistent with those...
HOOKIPA Pharma to Report First Quarter 2021 Financial Results on Wednesday, May 12, 2021
03. Mai 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, May 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
29. April 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, April 29, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...